NAD Augmentation in Diabetes Kidney Disease
This study is looking at whether a drug called MIB 626 (also known as NMN) can help people with type 2 diabetes and diabetic kidney disease. Diabetic kidney disease is when your kidneys are damaged because of diabetes. The study will compare MIB 626 to a placebo (a pill with no active medicine) to see if MIB 626 can reduce the amount of protein in your urine. A reduction in urine protein (measured by UACR, or urine albumin to creatinine ratio) would suggest the treatment is working. You can join if you are 30 years or older, have type 1 or type 2 diabetes, and have a certain level of protein in your urine. The current status of this study is unclear.
- Study design
- This is a randomized, double-blind, placebo-controlled study involving 156 participants. Participants will be randomly assigned to receive either MIB 626 or a placebo.
- What's involved
- Participants will receive MIB 626 or placebo twice daily for 6 months. The study will measure changes in your urine protein levels over this period.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 6 months, which is the duration of the intervention period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NAD Augmentation in Diabetes Kidney Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Shalender Bhasin, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The primary endpoint is the change from baseline in UACR over the 6-month intervention period.6 months
To determine whether treatment with a microcrystalline formulation of β nicotinamide mononucleotide (βNMN) in older adults with DKD improves urinary albumin to creatinine excretion ratio (UACR), compared to placebo.